CRM Biometrics GmbH Report issue

For profit Phase 2
Founded: Rheinbach Germany (1996)
Status: Acquired by Venn Life Sciences (2013)

Organization Overview

First Clinical Trial
2006
NCT00561691
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CRM Biometrics GmbH

Active Ingredients

Drugs in Phase 2 Trials (2)

bovine intestinal alkaline phosphatase (1 trial)

esflurbiprofen (1 trial)

Drugs in Other Trials (1)

nimotuzumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3